Anavex life sciences provides business update and reports fiscal 2021 third quarter financial results

New york, aug. 12, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today reported financial results for its fiscal quarter ended june 30, 2021.
AVXL Ratings Summary
AVXL Quant Ranking